TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6398121

Group type: EXPERIMENTAL
Intervention: R 14 regimen (cyclophosphamide 2 mg/kg/iv, vincristine 0.01 mg/kg/iv, vinblastine 0.1 mg/kg/iv, 5‐fluorouracil 5 mg/kg/iv, methotrexate 0.7 mg/kg/iv, adriamycin 0.5 mg/kg/iv every 21 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: CMF regimen (cyclophosphamide 100 mg/m2/po, methotrexate 40 mg/m2/iv, 5‐fluorouracil 600 mg/m2/iv)
Number of subjects: 46
Study: 30853809

Group type: EXPERIMENTAL
Intervention: Individual computer magnanimous therapy (ic‐mt)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Group computer magnanimous therapy (gc‐mt)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (ctrl)
Number of subjects: 145
Study: 29222641

Group type: COMPARATOR
Intervention: Ligasure™ 5 mm (LS)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Marseal™ IQ 5 mm (MS)
Number of subjects: 74
Study: 27362402

Group type: EXPERIMENTAL
Intervention: Imported histamine 1 mg/mL
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Locally-prepared histamine 1 mg/mL
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Locally-prepared histamine 5 mg/mL
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Locally-prepared histamine 10 mg/mL
Number of subjects: 75
Study: 24823906

Group type: EXPERIMENTAL
Intervention: Internet-based Climate Schools: Alcohol and Cannabis course (n=397, five schools)
Number of subjects: 764

Group type: COMPARATOR
Intervention: Usual health classes (n=367, five schools)
Number of subjects: 764
Study: 22410608

Group type: EXPERIMENTAL
Intervention: Rotated fixation method
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional fixation method
Number of subjects: 80
Study: 20413969

Group type: EXPERIMENTAL
Intervention: Olive-oil-enriched skim milk
Number of subjects: 36
Study: 18343177

Group type: EXPERIMENTAL
Intervention: L-arginine capsules
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 1
Study: 15963077

Group type: EXPERIMENTAL
Intervention: Rifaximin 600 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rifaximin 800 mg/day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg/day
Number of subjects: 90
Study: 12647599

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5 to 25 mg/day; n = 15,255)
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10 mg/day; n = 9,048)
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 to 40 mg; n = 9,054)
Number of subjects: 33357

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 33357

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 33357
Study: 10497444

Group type: EXPERIMENTAL
Intervention: Theophylline (5-20 micrograms/ml)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Theophylline (10-20 micrograms/ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 24

Group type: COMPARATOR
Intervention: Asthmatics
Number of subjects: 24
Study: 8712268

Group type: EXPERIMENTAL
Intervention: Unprotected sex with female sex workers
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Sexual experience and number of partners
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Intercourse before 18 years of age
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Number of partners
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Condom use with female sex workers
Number of subjects: 600
Study: 30907159

Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy intervention (twice-weekly sessions)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy intervention
Number of subjects: 11
Study: 30257783

Group type: EXPERIMENTAL
Intervention: Computer-navigated total knee arthroplasties
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional total knee replacements
Number of subjects: 30
Study: 27803231

Group type: EXPERIMENTAL
Intervention: High dose dual-antibiotic impregnated cement
Number of subjects: 848

Group type: COMPARATOR
Intervention: Low dose single-antibiotic impregnated cement
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 848
Study: 24848642

Group type: EXPERIMENTAL
Intervention: Piperlongumin (PL)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: β‐phenylethyl isothiocyanate (PEITC)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Lactic acidosis (LA)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: L‐buthionine sulfoximine (L‐BSO, 20 μM)
Number of subjects: 4
Study: 22324565

Group type: EXPERIMENTAL
Intervention: Attendance by a supportive significant other (SSO) during combined behavioral intervention (CBI) sessions
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: Presence of an SSO during drink refusal training session
Number of subjects: 776

Group type: EXPERIMENTAL
Intervention: SSO attendance at communication training session
Number of subjects: 776
Study: 21132610

Group type: EXPERIMENTAL
Intervention: Interspinous stand-alone spacer insertion (Aperius (®); Medtronic)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Microsurgical bilateral operative decompression
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interspinous stand-alone spacer insertion
Number of subjects: 36
Study: 17046182

Group type: EXPERIMENTAL
Intervention: Immediate discontinuation of hormone therapy (n=35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tapered discontinuation of hormone therapy (n=35)
Number of subjects: 70
Study: 16390401

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (amBisome) 50 mg daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional amphotericin B (amB) 15 mg daily
Number of subjects: 83
Study: 12926181

Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy with TA tree pollen and the immunoadjuvant monophosphoryl Lipid A
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo suspension containing 2% tyrosine
Number of subjects: 12
Study: 9426829

Group type: EXPERIMENTAL
Intervention: Interleukin-10
Number of subjects: 0
Study: 8535656

Group type: EXPERIMENTAL
Intervention: Combination of disease‐modifying antirheumatic drugs (DMARDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single DMARDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2650722

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2) monthly for up to 5 cycles
Number of subjects: 88

Group type: COMPARATOR
Intervention: Carboplatin (400 mg/m2) monthly for up to 5 cycles
Number of subjects: 88
Study: 882723

Group type: EXPERIMENTAL
Intervention: 0.15 mg isoproterenol sulfate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (freon propellent alone)
Number of subjects: 13
Study: 31095318

Group type: EXPERIMENTAL
Intervention: Training in interprofessional shared decision-making (SDM)
Number of subjects: 309

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 309
Study: 30052699

Group type: EXPERIMENTAL
Intervention: Weekly self-incentivizing (n = 44)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Monthly self-incentivizing (n = 50)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control (n = 65)
Number of subjects: 159
Study: 28739559

Group type: EXPERIMENTAL
Intervention: Clinic-based postnatal health check plus nurse-moderated Internet-based group support
Number of subjects: 819

Group type: COMPARATOR
Intervention: Standard care consisting of postnatal home-based support provided by a community nurse
Number of subjects: 819
Study: 25746057

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (no sevoflurane)
Number of subjects: 160
Study: 24138608

Group type: EXPERIMENTAL
Intervention: Evidence-based employment services at implementation sites
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Service visit
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Quality improvement approach
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Baseline surveys
Number of subjects: 801
Study: 20512497

Group type: EXPERIMENTAL
Intervention: Probiotic intervention with fermented milk prepared with Lactobacillus GG and L. gasseri TMC0356 for 10 weeks during pollen spread
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Probiotic intervention with fermented milk prepared with Lactobacillus GG and L. gasseri TMC0356
Number of subjects: 29
Study: 19332233

Group type: EXPERIMENTAL
Intervention: Baseline serum phosphorus >3.9 mg/dL
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Baseline calcium‐phosphorus product >36.8 mg(2)/dL(2)
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Average serum phosphorus (time-dependent model)
Number of subjects: 950
Study: 16846734

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,250 mg/m(2) Days 1 and 8 and paclitaxel 175 mg/m(2) as a 3‐h infusion on Day 1 (GP1)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m(2) Days 1 and 8 and paclitaxel 100 mg/m(2) as a 1‐h infusion on Days 1 and 8 (GP2)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m(2) Days 1 and 8 and docetaxel 40 mg/m(2) as a 1‐h infusion on Days 1 and 8 (GD)
Number of subjects: 210
Study: 12631049

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drinks (2 x 400 ml)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Carbohydrate with peptide drinks (2 x 400 ml)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fasting overnight with only water
Number of subjects: 48
Study: 11205196

Group type: EXPERIMENTAL
Intervention: Preoperative serum PIIINP concentration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 9-month serum PIIINP concentration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 12-month serum PIIINP concentration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 9-month serum CA125 concentration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 12-month serum CA125 concentration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Changes in serum CA125 concentration
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Preoperative PIIINP and 12-month CA125 concentrations
Number of subjects: 56
Study: 9200198

Group type: EXPERIMENTAL
Intervention: RMGI + DBA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RMGI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZP
Number of subjects: 0

Group type: COMPARATOR
Intervention: PC
Number of subjects: 0

Group type: COMPARATOR
Intervention: ZOE
Number of subjects: 0
Study: 1608114

Group type: EXPERIMENTAL
Intervention: Multidrug chemotherapy regimens
Number of subjects: 170
Study: 3919752

Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg of lormetazepam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg of flunitrazepam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29446084

Group type: EXPERIMENTAL
Intervention: PP1M (50-150 mg-eq)
Number of subjects: 1429

Group type: EXPERIMENTAL
Intervention: PP3M
Number of subjects: 1429

Group type: COMPARATOR
Intervention: PP1M
Number of subjects: 1429
Study: 26990723

Group type: EXPERIMENTAL
Intervention: Low-load group (LLG)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Moderate-load group (MLG)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 27
Study: 24834792

Group type: EXPERIMENTAL
Intervention: Lifestyle changes (diet and exercise) during pregnancy
Number of subjects: 360

Group type: COMPARATOR
Intervention: Routine pregnancy care (Control)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Gestational weight gain ≤9 kg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Gestational weight gain >9 kg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Postpartum weight retention ≤5 kg
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Postpartum weight retention >5 kg
Number of subjects: 360
Study: 22436170

Group type: EXPERIMENTAL
Intervention: Ondasetron 8 mg iv
Number of subjects: 80

Group type: COMPARATOR
Intervention: Haloperidol 5 mg iv
Number of subjects: 80
Study: 20162580

Group type: EXPERIMENTAL
Intervention: Magnetoencephalography (MEG) analysis of S1 and M1 areas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of S1-M1 dynamic recruitment with thalamic volume
Number of subjects: 0
Study: 18955908

Group type: EXPERIMENTAL
Intervention: Viewing point-light dot animations of biological motion (specifics on dosage and duration not available)
Number of subjects: 2
Study: 16779172

Group type: EXPERIMENTAL
Intervention: CoViSTA system (Computerized Vital Sign Transfer Application)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Current practice of collecting vital signs
Number of subjects: 60
Study: 12123126

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both MMF and Azathioprine
Number of subjects: 26
Study: 10220643

Group type: EXPERIMENTAL
Intervention: Salivary cotinine
Number of subjects: 5164

Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked per day
Number of subjects: 5164
Study: 8558750

Group type: EXPERIMENTAL
Intervention: Initial bolus dose of 30% rt-PA (41.4 mg) followed by infusion over 60 min
Number of subjects: 82

Group type: COMPARATOR
Intervention: Initial bolus dose of 10% rt-PA (41.4 mg) followed by infusion over 60 min
Number of subjects: 82
Study: 2142189

Group type: EXPERIMENTAL
Intervention: Participation in a stroke club (experimental)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No participation in a stroke club (control)
Number of subjects: 38
Study: 6452463

Group type: EXPERIMENTAL
Intervention: Erythromycin, 1.5% topical solution (n = 127)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Vehicle (n = 126)
Number of subjects: 253
Study: 30304644

Group type: EXPERIMENTAL
Intervention: REACH-HF intervention (facilitated self-care and home-based cardiac rehabilitation programme)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study: 30170024

Group type: EXPERIMENTAL
Intervention: Hydrogels (Level 1 - syrup, Level 2 - custard, Level 3 - pudding)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 30
Study: 28974250

Group type: EXPERIMENTAL
Intervention: Urodynamics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 26048602

Group type: COMPARATOR
Intervention: Conventional occupational therapy (5 times per week)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Conventional occupational therapy (3 times per week) + differential training-based occupational therapy (2 times per week)
Number of subjects: 27
Study: 24565295

Group type: EXPERIMENTAL
Intervention: Group HDO (ondansetron 8 mg, dexamethasone 8 mg, haloperidol 2 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group O (ondansetron 8 mg)
Number of subjects: 90
Study: 21059869

Group type: EXPERIMENTAL
Intervention: 0.2% FGF-2
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: 0.3% FGF-2
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: 0.4% FGF-2
Number of subjects: 253

Group type: COMPARATOR
Intervention: Vehicle alone (0% FGF-2)
Number of subjects: 253
Study: 18774696

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17208898

Group type: EXPERIMENTAL
Intervention: ABC/3TC/ZDV (300/150/300 mg) and TDF (300 mg) once daily
Number of subjects: 123
Study: 12712083

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal saline solution placebo
Number of subjects: 68
Study: 10834422

Group type: EXPERIMENTAL
Intervention: Injected liquid silicone (6 injections of 0.2 ml)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 28
Study: 9663840

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg b.d.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.d. plus amoxycillin 1000 mg b.d.
Number of subjects: 122
Study: 8130290

Group type: EXPERIMENTAL
Intervention: Individualized instructional program
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Self-instructional program
Number of subjects: 42
Study: 3698813

Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30992480

Group type: EXPERIMENTAL
Intervention: Professional continuous glucose monitoring (p-CGM) with SMBG
Number of subjects: 68

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG) alone
Number of subjects: 68
Study: 29327449

Group type: EXPERIMENTAL
Intervention: LLLT + SRP
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study: 26814305

Group type: EXPERIMENTAL
Intervention: Group assessment format (supported self-assessment)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Individual assessment
Number of subjects: 211
Study: 26437939

Group type: EXPERIMENTAL
Intervention: Planning condition
Number of subjects: 160

Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 160
Study: 22116795

Group type: EXPERIMENTAL
Intervention: NMES training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 20
Study: 20543741

Group type: EXPERIMENTAL
Intervention: Decreasing rest intervals (DIs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Constant rest intervals (CIs)
Number of subjects: 20
Study: 18758356

Group type: EXPERIMENTAL
Intervention: Epidural methylprednisolone 40 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 200
Study: 15899442

Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (Focus Night & Day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Etafilcon A (Acuvue)
Number of subjects: 100
Study: 12571466

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg per day for 4 consecutive days once monthly for 6 months, n = 15)
Number of subjects: 23

Group type: COMPARATOR
Intervention: IVIg (800 mg/kg intravenously once monthly for 6 months, n = 8)
Number of subjects: 23
Study: 10850589

Group type: EXPERIMENTAL
Intervention: ATG Fresenius S (9 mg/kg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no ATG)
Number of subjects: 76
Study: 8577016

Group type: EXPERIMENTAL
Intervention: Structured lipids (1.0 g/kg per day in part 1, 1.5 g/kg per day in part 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT) (1.0 g/kg per day in part 1, 1.5 g/kg per day in part 2)
Number of subjects: 0
Study: 3155240

Group type: COMPARATOR
Intervention: No treatment for the first 10 days of the disease
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Immunoglobulin treatment
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: High doses of steroids
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 138
Study: 1210468

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (intraarticular treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone (local applications)
Number of subjects: 0
Study: 31195825

Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral DCB
Number of subjects: 331

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 331
Study: 28522351

Group type: EXPERIMENTAL
Intervention: Early supplemental parenteral nutrition (PN)
Number of subjects: 1440
Study: 26137564

Group type: EXPERIMENTAL
Intervention: High-dose patritumab
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Low-dose patritumab
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 23314982

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4,000 IU daily for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (optimal medical therapy without vitamin D supplementation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 21606648

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3,600 mg/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 18642635

Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Traditional intervention (control treatment)
Number of subjects: 22
Study: 21411701

Group type: EXPERIMENTAL
Intervention: Interferon‐α/β receptor expression
Number of subjects: 40
Study: 27945235

Group type: EXPERIMENTAL
Intervention: HF-ACC-RCT with 5-FU (600mg/m²/d) and carboplatin (70mg/m²/d) on days 1-5 and 29-33
Number of subjects: 263

Group type: COMPARATOR
Intervention: HF-ACC RT alone
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: HF-ACC-RCT
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Pretherapeutical Hb levels >13.5 g/dl
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Pretherapeutical Hb levels <12.7 g/dl and >14.75 g/dl
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: RCT and RT
Number of subjects: 263
Study: 11814373

Group type: EXPERIMENTAL
Intervention: Daily supplementation (Group A, n = 70) - 350 mg ferrous sulfate and 1.5 mg folic acid once daily for 90 to 100 days
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Weekly supplementation (Group B, n = 67) - same dosage as Group A but administered once a week for 14 weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (Group C, n = 72) - no supplementation
Number of subjects: 209
Study: 9588656

Group type: EXPERIMENTAL
Intervention: Physical training (3-4 times a week at 70% maximum capacity for 6 months)
Number of subjects: 229
Study: 8047802

Group type: EXPERIMENTAL
Intervention: Domperidone plus magnesium hydroxide and aluminum hydroxide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Domperidone plus alginate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Domperidone alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 2903057

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide, methotrexate and 5-fluorouracil
Number of subjects: 1629

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1629
Study: 807223

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 603

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 603